

Category : **ICU organization**

A159 - Early outcomes and intensive care unit length of stay with rezafungin once-weekly echinocandin in invasive candida disease

A Soriano¹ ; S Dickerson² ; A Das³ ; T Sandison³ ; GR Thompson⁴

¹Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Department of Infectious Diseases, Barcelona, Spain, ²Mundipharma, Cambridge, United Kingdom, ³Cidara Therapeutics, San Diego, United States, ⁴University of California Davis Medical Center, California, United States

Introduction:

The Phase 2 double-blind randomized STRIVE trial (NCT02734862) examined the efficacy of rezafungin, a next-generation once-weekly echinocandin demonstrating a prolonged half-life and high front-loaded plasma exposures, in the treatment of candidaemia and invasive candidiasis (IC). Early treatment outcomes and length of stay (LOS) in the intensive care unit (ICU) are presented.

Methods:

Adults (≥18 years) with candidemia and/or IC were randomised to receive rezafungin 400/400 mg (400 mg once-weekly), rezafungin 400/200 mg (Week 1: 400 mg; 200 mg once-weekly thereafter), or caspofungin (Day 1:70 mg; 50 mg daily thereafter) for ≤4 weeks. Day 5 overall cure and mycological success rates were evaluated. Post-hoc analysis examined time to negative blood culture, blood culture clearance at 24 and 48 hours, and ICU LOS (based on discharge from ICU excluding discharge due to death) data.

Results:

The percentages of patients with negative blood cultures are presented in Table 1 along with early overall and mycological outcomes.

At enrolment, 44% (80/183) of subjects were in the ICU, with a further 6% (11/183) admitted during the trial (microbiological intention-to-treat [mITT] population). Table 1 shows median ICU LOS data for each study arm.

Conclusion:

Early treatment efficacy of rezafungin was demonstrated by the outcomes of negative blood culture at 24 and 48 hours and day 5 overall response rate. A shorter ICU median LOS was also observed in the rezafungin group. These findings support the high front-loaded plasma exposure as a pharmacometric determinant of efficacy in patients with candidemia or IC in the ICU.

Table:

Parameter	Rezafungin 400/400 mg (N=76)	Rezafungin 400/200 mg (N=46)	Caspofungin 70/50 mg (N=61)
Negative blood culture at 24 hours, % (n/N)	74.1 (43/58)	73.7 (28/38)	54.0 (27/50)
Negative blood culture at 48 hours, % (n/N)	86.0 (49/57)	86.1 (31/36)	65.3 (32/49)
Mycological Cure (Day 5), % (n)	65.8 (50)	76.1 (35)	62.3 (38)
Overall Success (Day 5), % (n)	55.3 (42)	73.9 (34)	55.7 (34)
ICU patients, % (n)	31.6 (24)	39.1 (18)	37.7 (23)
Median length of stay in the ICU, days (Min, Max)	13.0 (1-79)	13.0 (2-48)	18.0 (1-61)

Early Treatment Outcomes and ICU Length of Stay in the STRIVE Trial (mITT population)